These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 23212243)

  • 21. Minor Nonintracranial Hemorrhage and Poor Prognosis among Stroke Patients Undergoing Intravenous Thrombolysis.
    Qin X; Zhao S; Yin L; Dou H; Chen J; Wang Y; Li M; Chen R; Yang G; Liu X; Wang R; Jia X; Bu S; Ma D; Wang B; Li S
    J Stroke Cerebrovasc Dis; 2017 Oct; 26(10):2383-2386. PubMed ID: 28624140
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic value of plasma HMGB1 in ischemic stroke patients with cerebral ischemia-reperfusion injury after intravenous thrombolysis.
    Wang J; Jiang Y; Zeng D; Zhou W; Hong X
    J Stroke Cerebrovasc Dis; 2020 Sep; 29(9):105055. PubMed ID: 32807461
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hesperidin reduces adverse symptomatic intracerebral hemorrhage by promoting TGF-β1 for treating ischemic stroke using tissue plasminogen activator.
    Qin Z; Chen L; Liu M; Tan H; Zheng L
    Neurol Sci; 2020 Jan; 41(1):139-147. PubMed ID: 31478148
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined anti-platelet therapy with aspirin and clopidogrel: risk factor for thrombolysis-related intracerebral hemorrhage in acute ischemic stroke?
    Hermann A; Dzialowski I; Koch R; Gahn G
    J Neurol Sci; 2009 Sep; 284(1-2):155-7. PubMed ID: 19473668
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictors of in-hospital mortality and the risk of symptomatic intracerebral hemorrhage after thrombolytic therapy with recombinant tissue plasminogen activator in acute ischemic stroke.
    Al-Khaled M; Matthis C; Eggers J
    J Stroke Cerebrovasc Dis; 2014 Jan; 23(1):7-11. PubMed ID: 22578915
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changes in Activated Thrombin-Activatable Fibrinolysis Inhibitor Levels Following Thrombolytic Therapy in Ischemic Stroke Patients Correlate with Clinical Outcome.
    Alessi MC; Gaudin C; Grosjean P; Martin V; Timsit S; Mahagne MH; Larrue V; Sibon I; Zuber M; Brouns R; Montaner J; Castellanos M; Donazzolo Y; Cho TH; Suissa L; Mechtouff L; Derex L; Suchon P; Mezzapesa A; Nighoghossian N
    Cerebrovasc Dis; 2016; 42(5-6):404-414. PubMed ID: 27387478
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The impact of intracranial carotid artery calcification on the development of thrombolysis-induced intracerebral hemorrhage.
    Lin TC; Chao TH; Shieh Y; Lee TH; Chang YJ; Lee JD; Peng TI; Chang KC; Liou CW; Chang TY; Hung KL; Chang CH
    J Stroke Cerebrovasc Dis; 2013 Nov; 22(8):e455-62. PubMed ID: 23800497
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Symptomatic intracranial hemorrhage following intravenous thrombolysis for acute ischemic stroke: a critical review of case definitions.
    Seet RC; Rabinstein AA
    Cerebrovasc Dis; 2012; 34(2):106-14. PubMed ID: 22868870
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fibrinogen concentrate replacement in ischemic stroke patients after recombinant tissue plasminogen activator treatment.
    Vandelli L; Marietta M; Trenti T; Varani M; Bigliardi G; Rosafio F; Dell'acqua ML; Picchetto L; Nichelli P; Zini A
    Adv Clin Exp Med; 2019 Feb; 28(2):219-222. PubMed ID: 30507073
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of stroke prognostication using age and NIH Stroke Scale index (SPAN-100 index) in delayed intravenous thrombolysis patients (beyond 4.5 hours).
    Elsaid N; Bigliardi G; Dell'Acqua ML; Vandelli L; Ciolli L; Picchetto L; Borzì G; Ricceri R; Pentore R; Vallone S; Meletti S; Saied A
    J Stroke Cerebrovasc Dis; 2022 Apr; 31(4):106384. PubMed ID: 35182948
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety of intravenous thrombolytic use in four emergency departments without acute stroke teams.
    Scott PA; Frederiksen SM; Kalbfleisch JD; Xu Z; Meurer WJ; Caveney AF; Sandretto A; Holden AB; Haan MN; Hoeffner EG; Ansari SA; Lambert DP; Jaggi M; Barsan WG; Silbergleit R
    Acad Emerg Med; 2010 Oct; 17(10):1062-71. PubMed ID: 21040107
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Derivation and Validation of a Scoring System for Intravenous Tissue Plasminogen Activator Use in Asian Patients.
    Yeo LLL; Chien SC; Lin JR; Liow CW; Lee JD; Peng TI; Luen TH; Sharma V; Chan B; Lee TH;
    J Stroke Cerebrovasc Dis; 2017 Aug; 26(8):1695-1703. PubMed ID: 28408066
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Frequency and predictors of symptomatic intracerebral hemorrhage in patients with ischemic stroke treated with recombinant tissue plasminogen activator outside clinical trials.
    Martí-Fàbregas J; Bravo Y; Cocho D; Martí-Vilalta JL; Díaz-Manera J; San Román L; Puig M; Blanco M; Castellanos M; Millán M; Roquer J; Obach V; Maestre J
    Cerebrovasc Dis; 2007; 23(2-3):85-90. PubMed ID: 17114877
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A case-controlled comparison of thrombolysis outcomes between wake-up and known time of onset ischemic stroke patients.
    Manawadu D; Bodla S; Jarosz J; Keep J; Kalra L
    Stroke; 2013 Aug; 44(8):2226-31. PubMed ID: 23723307
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictors of hemorrhagic transformation after intravenous recombinant tissue plasminogen activator: prognostic value of the initial apparent diffusion coefficient and diffusion-weighted lesion volume.
    Selim M; Fink JN; Kumar S; Caplan LR; Horkan C; Chen Y; Linfante I; Schlaug G
    Stroke; 2002 Aug; 33(8):2047-52. PubMed ID: 12154261
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical deterioration after intravenous recombinant tissue plasminogen activator treatment: a multicenter transcranial Doppler study.
    Saqqur M; Molina CA; Salam A; Siddiqui M; Ribo M; Uchino K; Calleja S; Garami Z; Khan K; Akhtar N; O'Rourke F; Shuaib A; Demchuk AM; Alexandrov AV;
    Stroke; 2007 Jan; 38(1):69-74. PubMed ID: 17138949
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pretreatment hemostatic markers of symptomatic intracerebral hemorrhage in patients treated with tissue plasminogen activator.
    Cocho D; Borrell M; Martí-Fàbregas J; Montaner J; Castellanos M; Bravo Y; Molina-Porcel L; Belvís R; Díaz-Manera JA; Martínez-Domeño A; Martínez-Lage M; Millán M; Fontcuberta J; Martí-Vilalta JL
    Stroke; 2006 Apr; 37(4):996-9. PubMed ID: 16497981
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intracerebral hemorrhage after thrombolytic therapy in acute ischemic stroke patients with renal dysfunction.
    Chao TH; Lin TC; Shieh Y; Chang TY; Hung KL; Liu CH; Lee TH; Chang YJ; Lee JD; Chang CH
    Eur Neurol; 2013; 70(5-6):316-21. PubMed ID: 24080988
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Time to recanalization and risk of symptomatic intracerebral haemorrhage in patients treated with intravenous thrombolysis.
    Dorado L; Millán M; Pérez de la Ossa N; Guerrero C; Gomis M; Aleu A; López-Cancio E; Cuadras P; Dávalos A
    Eur J Neurol; 2012 Sep; 19(9):1251-5. PubMed ID: 22568604
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Symptomatic Intracerebral Hemorrhage after Intravenous Thrombolysis: Predictive Factors and Validation of Prediction Models.
    Nisar T; Hanumanthu R; Khandelwal P
    J Stroke Cerebrovasc Dis; 2019 Nov; 28(11):104360. PubMed ID: 31501036
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.